Premium
Treatment of ankylosing spondylitis with co‐amoxiclav
Author(s) -
Öğrendik Mesut
Publication year - 2018
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12952
Subject(s) - ankylosing spondylitis , medicine , spondylitis , gastroenterology
Summary This article presents the efficacy of co‐amoxiclav in two patients with ankylosing spondylitis. Both patients were administered oral co‐amoxiclav for 7 days. The primary efficacy variable was the ankylosing spondylitis activity index. Secondary outcome measures were the ankylosing spondylitis functional index and spinal mobility. We detected a marked improvement in all symptoms and physical examination parameters. Co‐amoxiclav has been shown to be effective against ankylosing spondylitis.